The role of alpha-actinin-4 in human kidney disease by unknown
Feng et al. Cell Biosci  (2015) 5:44 
DOI 10.1186/s13578-015-0036-8
REVIEW
The role of alpha-actinin-4 in human 
kidney disease
Di Feng1, Clark DuMontier2 and Martin R Pollak1*
Abstract 
Mutations in the Alpha-actinin-4 gene (ACTN4) cause a rare form of familial focal segmental glomerulosclerosis in 
humans. Individuals with kidney disease-associated ACTN4 mutations tend to have mild to moderate proteinuria, 
with many developing decreased kidney function progressing to end stage kidney disease. All of the disease-causing 
ACTN4 mutations identified to date are located within the actin-binding domain of the encoded protein, increasing 
its binding affinity to F-actin and leading to abnormal actin rich cellular aggregates. The identification of ACTN4 muta-
tions as a cause of human kidney disease demonstrates a key cellular pathway by which alterations in cytoskeletal 
behavior can mediate kidney disease. Here we review the studies relevant to ACTN4 and its role in mediating kidney 
disease.
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Background
Focal segmental glomerulosclerosis (FSGS) is a common 
histologic pattern of kidney injury, often associated with 
progressive chronic kidney disease and overt kidney fail-
ure. FSGS is defined histologically by sclerosis occurring 
in a portion of the glomerulus and affecting a subset of 
glomeruli. While these biopsy features define a pattern 
of injury, they do not define the underlying etiology [1]. 
Electron microscopy typically shows fusion of epithelial 
cell foot processes, or so-called foot process effacement. 
Common features of FSGS patients include proteinuria, 
edema, hypertension and hypercholesterolemia.
FSGS is found in about 20–25% of all renal biopsies 
[2, 3]. However, the incidence and prevalence of FSGS 
in children may be underestimated [4]. This is because 
many children with nephrotic syndrome (NS), defined 
as heavy proteinuria, hypoalbuminemia, and peripheral 
edema, are generally assumed to have minimal change 
syndrome and not subjected to renal biopsy. Even when 
a biopsy is performed, the characteristic lesion necessary 
for diagnosis might not be captured in the sample. It is 
estimated that the incidence of NS in children is between 
2 and 4 new cases per 100,000 children per year, with 
biopsy-confirmed FSGS comprising 15–20% [4, 5]. The 
prevalence of FSGS continues to increase for unknown 
reasons [2, 5, 6]. FSGS is seen in approximately 2–5% 
of cases of end stage renal disease (ESRD) in adults and 
about 10% in children [7].
A number of etiologies have been associated with FSGS 
and are often used as the basis for further classification. 
Broadly, FSGS is divided into primary (idiopathic) and 
secondary forms. Secondary FSGS is thought to result 
from a wide range of systemic conditions, including 
reflex nephropathy, heroin use, decreased renal mass, 
hypertension, diabetes, obesity, and HIV infection [8, 
9]. In comparison with secondary FSGS, primary FSGS 
is more likely to present with nephrotic-range proteinu-
ria and have a poorer prognosis, with 50% progressing 
to ESRD over 3–8 years ([9, 10]. For FSGS patients with 
nephrotic-range proteinuria, the use of corticosteroids 
is associated with an increased likelihood of a remission 
[9, 11]. However, steroid resistance can be present in up 
to 50% of patients, and a prolonged steroid treatment is 
associated with significant side effects [9]. Therefore, 
there is great interest in understanding the molecular 
mechanisms underlying different forms of FSGS and kid-
ney injury. Mutations in several genes are associated with 
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familial forms of FSGS or nephrotic syndrome, including 
α-actinin-4 (here we use ACTN4 to designate the human 
gene or protein and Actn4 to designate the mouse gene 
or protein) [12], inverted formin 2 (INF2) [13], canonical 
transient receptor potential 6 (TRPC6) [14, 15], nephrin 
(NPHS1) [16], and podocin (NPHS2) [17]. This review 
will focus on ACTN4 and its role in mediating human 
FSGS.
The α-actinins are 100  kD rod shaped proteins that 
form head-to-tail homodimers [18]. α-Actinin mono-
mers contain three distinct domains: an N-terminal 
actin binding domain (ABD), four spectrin-like repeats 
(SRs), and a C-terminal EF hands (calmodulin like 
domain). There are four human α-actinin (ACTN1-4) 
family members, encoding closely related actin crosslink-
ing proteins. ACTN2 and ACTN3 (calcium insensitive) 
show sarcomere-limited expression [19]. The non-mus-
cle cytoskeletal ACTN1 (highly calcium sensitive) and 
ACTN4 (moderately calcium sensitive), appear to be 
widely expressed [20, 21]. However, for unclear reasons, 
the human phenotype associated with ACTN4 mutations 
is apparent only in the kidney [12]. Additionally, ACTN1 
mutations were identified as a cause of congenital mac-
rothrombocytopenia, an inherited disorder showing 
low platelet counts [22]. ACTN2 mutations have been 
found in rare families with hypertrophic cardiomyopathy 
[23]. The ACTN3 R577X variant, leading to absence of 
ACTN3 protein due to an early stop-codon, is absent in 
18% of healthy white individuals [24]. There is no appar-
ent disease phenotype as a result of this variant. How-
ever, the homozygous genotype appears with very low 
frequency in elite sprint athlete [25]. The loss of ACTN3 
is associated with reduced skeleton high velocity contrac-
tion. Altogether, these studies revealed unique roles of 
different α-actinin isoforms different tissues.
In addition to bundling F-actin, ACTN4 interacts with 
various other proteins, consistent with multiple roles 
in cell function. Some of these studies were conducted 
either using crude extraction of α-actinin or anti-α-
actinin antibodies that are not specific for ACTN4. For 
example:
1. Cell adhesion α-actinins interact directly with 
β1-integrin [26, 27], vinculin [28, 29], zyxin [30], 
kindlin-1 [31] to modulate focal adhesion, and to link 
the cytoskeleton to the extracellular matrix.
2. Cell junction The glomerular slit diaphragm between 
podocyte foot processes shares many morphologic 
features with the adherens junction seen in epithe-
lial cells. The glomerular slit diaphragm composes 
of P-cadherin, α-catenin, β-catenin, γ-catenin, and 
ZO-1 [32]. α-actinins have been shown to inter-
act directly with α-catenin [33]. Moreover, the slit-
diaphragm protein nephrin appears to form a major 
structural component of the slit diaphragm between 
adjacent podocytes. ACTN4, together with five other 
cell junction proteins, including the membrane-
associated guanylate kinase inverted 2_synaptic 
scaffolding molecule (MAGI-2/S-SCAM), IQ motif-
containing GTPase activating protein1 (IQGAP1), 
αII spectrin, and βII spectrin was detected as part of 
the neprhin multiprotein complex [34]. Therefore, 
ACTN4 could serve as a linker between F-actin and 
other adherens junction proteins.
3. Cell signaling One of the key signaling molecules 
phosphatidylinositol 4,5-bisphosphate (PIP2) was 
shown to bind α-actinin at the plasma membrane. 
Upon PI3 Kinase (PI3K) activation, PIP2 is converted 
to phosphatidylinositol 3,4,5-trisphosphate (PIP3), 
which decreases the association of α-actinin to actin 
filament within stress fibers, as well as the association 
rate to integrin within focal adhesions [35, 36]. More-
over, ACTN4 can interact PI3K downstream kinase 
Akt to mediate cell proliferation [37]. Finally, PIP3 
binding ACTNs also increases their susceptibility to 
calpain-1 and -2-mediated proteolysis [38].
4. Nuclear transcription activator ACTN4 was reported 
to be present in cell nuclei in 1998 [39]. Notably, PI3K 
inhibition and actin depolymerization both pro-
mote nuclear accumulation of ACTN4. Since then, 
ACTN4 has been reported to be a transcription acti-
vator of the estrogen receptor (ERα) [40, 41], the reti-
noic acid receptor (RAR) [42], the myocyte enhancer 
factor (MEF) [43, 44], the vitamin D receptor [41], 
the androgen receptor [45], NF-ķB transcription fac-
tors [46], thus potentially regulating transcription 
activity of multiple genes.
ACTN4 mutations in humans with FSGS
Positional cloning approaches identified three different 
point mutations in ACTN4 as the cause of FSGS in three 
unrelated families [12]. These families show autosomal 
dominant inheritance of disease, with high but incom-
plete penetrance and variable expressivity. Most of the 
affected individuals initially presented with low-grade 
proteinuria mainly in early adulthood with declining kid-
ney function that slowly progressed to ESRD. The K255E, 
T259I, and S262P mutations identified in these families 
are all located within the evolutionarily conserved ABD 
of ACTN4. As assessed by actin filament co-sedimenta-
tion assays, all mutations are associated with increased 
ACTN4 binding affinity to F-actin. ACTN4, but not 
ACTN1, is expressed at high levels (as detected by west-
ern blot) in human kidney. By immunofluorescence 
staining, it was found that ACTN4 is most prominently 
distributed in podocytes, with some distribution in other 
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vasculature in the renal cortex. These findings are con-
sistent with previous reports, suggesting that ACTN4 is 
highly expressed in podocytes, and with less expression 
elsewhere within the kidney [47, 48].
Two additional missense mutations in the ABD, W59R 
and I149del, were subsequently defined as disease-caus-
ing based on the following criteria: (1) mutants formed 
abnormal cellular aggregates with F-actin within the 
cell; (2) these mutations increased binding affinity of 
ACTN4 to F-actin, (3) ACTN4 with these mutations co-
segregated with affected individuals within families; (4) 
the mutations occur in evolutionarily-conserved ABD 
domain [49]. ACTN4 mutations (five total disease-caus-
ing mutations including the three previously discovered) 
accounted for approximately 3.5% of 141 familial FSGS 
cases screened in this study. The W59R substitution iden-
tified in this study was of particular interest as it was a de 
novo mutation not present in the proband’s parent. This 
individual exhibited proteinuria at age 5 and progressed 
to ESRD within 3  years, much earlier than other fami-
lies with ACTN4 mutations. In addition, this individual 
developed recurrent proteinuria and FSGS after trans-
plantation, the only such case reported to date.
Another clinical report documented a germline mosai-
cism ACTN4 mutation at S262F in the father of two 
affected siblings [50]. This mutation occurs at the same 
location as the previously reported heterozygous muta-
tion S262P. Both patients developed FSGS in early child-
hood (3–4  years old) and rapidly progressed to ESRD. 
Renal biopsy showed a collapsing variant of FSGS in one 
affected sibling, a histological subtype of FSGS associ-
ated with a poorer prognosis. All of the disease causing 
ACTN4 mutations and their location in ABD has been 
summarized in Fig. 1 [51, 52].
Actn4 mouse models
Kos et  al. generated Actn4 knockout (Actn4 KO) mice 
[53]. A significant percentage of homozygous Actn4 KO 
mice suffer perinatal death. The remaining survivors go 
on to develop albuminuria and FSGS at about 10 weeks 
of age. Transmission electron microscopy of these 
Actn4 KO mice shows podocyte foot-process efface-
ment. There is no clear alteration in podocin, nephrin, 
or type IV collagen expression in homozygous Actn4 
KO mice by immunofluorescence staining. Even though 
strong expression of both Actn1 and Actn4 are detected 
in wild type (WT) mouse podocytes, the loss of Actn4 
alone leads to a significant renal phenotype, suggesting 
that Actn4 plays a nonreduntant role in the mouse kid-
ney. Additionally, homozygous Actn4 KO mice also show 
a decrease in the number of podocytes in the glomeruli, 
and a significant increased number of podocytes shed-
ding in the urine as indicated by the presence of podo-
cyte marker WT-1 protein [54]. Podocytes isolated from 
homozygous Actn4 KO mice showed decreased phos-
phorylation of β1-integrin and weaker integrin-cytoskel-
eton linkages. Consequently, They also showed decreased 
attachment in response to shear stress in culture. Alto-
gether, homozygous Actn4 KO mice demonstrated the 
importance of the expression level of Actn4 in kidney 
disease. Indeed, Liu et al. reported that decreased expres-
sion of ACTN4 could occur in humans with primary glo-
merulopathies including sporadic FSGS, minimal change 
disease, and IgA nephropathy [55].
Yao et  al. generated Actn4 K256E (a mutation analo-
gous to the FSGS-causing K255E mutation in humans) 
knock-in (Actn4 KI) mice in an effort to mimic the 
human phenotype [56]. Homozygous Actn4 KI mice also 
showed perinatal lethality, albuminuria, and podocyte 
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Fig. 1 Functional domains of the human ACTN4 protein. The actin-binding domain (ABD) consists of CH1 (amino acid 47–154) and CH2 domain 
(amino acid 165–268). Mutations within ACTN4 including W59R and I149del in the CH1 domain and K255E, T259I, S262P and S262F in the CH2 
domain have been associated with human FSGS.
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foot enfacement as seen in the Actn4 KO mice. Hender-
son et al. further examined the pathological characteriza-
tion of both K256E and KO mice [57]. Both homozygous 
KI and KO mice exhibit the phenotype of collapsing glo-
merulopathy. Actn4 KI and KO mice did not survive past 
21 and 15 weeks respectively. Homozygous KI mice and 
all KO mice show decreased expression of podocyte dif-
ferentiation markers, including WT-1 and synaptopodin, 
and increased proliferation markers, including cyclin 
D1 and KI-67. Heterozygous Actn4 KI mice represent a 
more genetically faithful model for the autosomal-domi-
nant ACTN4-mediated FSGS in humans. These mice did 
not develop glomerulosclerosis during the 70-week study 
period. However, they did exhibit focal glomerular hyper-
trophy and mild glomerular ultrastructural abnormali-
ties, including mild podocyte cell body abnormalities, 
glomerular basement membrane (GBM) thickening and 
redundancy, and diffuse electron-dense aggregate accu-
mulation. These abnormalities in heterozygous Actn4 
KI mice may increase susceptibility to injury caused by 
other genetic or environmental stressors.
Michaud et  al. generated podocyte-specific (driven by 
murine nephrin promoter) transgenic mice that overex-
pressed the K256E mutation (homologus to the human 
K255E mutation) [58]. Podocyte specific K256E mutant 
(K256E-Actn4pod) mice show heterogeneity, potentially 
due to variation in the expression of the transgene. The 
transgenic mice that had higher expression of mutant 
Actn4 exhibited significant albuminuria, glomeruloscle-
rosis, and foot process enfacement at 10  weeks of age. 
These proteinuric transgenic mice also showed reduced 
expression of nephrin. Both proteinuric and non-pro-
teinuric Actn4 transgenic mice exhibited increased aver-
age systolic BP measured by tail-cuff plethysmography. 
Michaud et  al. also generated podocyte-specific trans-
genic mice overexpressing the wild-type Actn4 (WT-
Actn4pod) as a control line of mice. They showed that 
WT-Actn4pod mice are indistinguishable from their non-
transgenic littermates [59]. These mice do not develop 
albuminuria, glomerulosclerosis, foot process enface-
ment, or elevated systemic blood pressure. The authors 
concluded that it is the K256E Actn4 mutation, not the 
overexpression of Actn4, underlies the FSGS phenotype 
in K256E-Actn4pod.
Mechanisms by which ACTN4 mutations lead FSGS
Several studies have examined the effect of ACTN4 
mutations on protein function in  vitro. Weins et  al. 
found that K255E mutant ACTN4 (full length or ABD) 
shows greater binding affinity to F-actin compared to 
WT ACTN4 based on co-sedimentation studies [60]. The 
addition of Ca2+ decreased the binding affinity of WT 
ACTN4 to F-actin, but not K255E ACTN4. These results 
suggest that K255E mutant ACTN4 binding to F-actin is 
not subject to Ca2+ regulation in  vitro. One hypothesis 
proposed in this study is that a conformational change 
occurs when mutant K255E binds to F-actin, resulting in 
greater binding affinity. Interestingly, the crystal struc-
ture of the ABD of mutant K255E ACTN4 in absence of 
actin shows the same conformation as the WT protein 
[52]. Perhaps, the F-actin bound form of ACTN4 adopts 
a different structural conformation than ACTN4 alone. 
Galkin et al. used cryo-electron microscopy reconstruc-
tion (relative low resolution) of F-actin cross-linked by 
ABD of ACTN4 to build a model. They predicted that 
the bound form of ACTN4 would adopt a different con-
formation than the unbound ACTN4 crystal structure 
to enable binding to F-actin [61]. Therefore, the high-
resolution cryo-electron microscopy structure of F-actin 
cross-linked by mutant ACTN4 is needed to better 
explain how mutations lead to binding affinity changes of 
ACTN4 to F-actin, and to visualize the exact conforma-
tional changes.
Weins et  al. used electron microscopy to examine the 
appearance of actin filaments cross-linked either by WT 
or K255E mutant ACTN4 in vitro [60]. They showed that 
WT ACTN4 crosslinks actin filaments into thick parallel 
bundles with defined spacing. On the other hand, mutant 
ACTN4 induces the formation of a disordered and entan-
gled network of thin filament bundles. Similarly, under 
fluorescent microscopy, actin filaments (fluorescently 
labeled) cross-linked by WT ACTN4 form an evenly 
spaced and finely reticulated actin network. In com-
parison, actin filaments cross-linked by K255E mutant 
ACTN4 form a more coarsely reticulated network with 
a smaller mesh size [62]. Based on bulk rheology experi-
ments, Ward et  al. suggested that the dissociation of 
mutant K255E ACTN4 from actin is much slower than 
the WT ACTN4. Additionally, Yao et  al. observed that 
the actin network cross-linked by K255E mutant ACTN4 
is more brittle, with a lower breaking stress in compari-
son to networks cross-linked with WT [63]. Together, 
these in  vitro studies reflect how mutations within 
ACTN4 change the intrinsic biochemical and biophysical 
properties of the protein.
The effects of K255E mutant ACTN4 on cellular func-
tions have also been examined. Using immortalized lung 
fibroblasts and podocytes isolated from homozygous 
Actn4 KI mice, Weins et al. observed that mutant Actn4 
aggregates with F-actin [60]. Biopsies from patients 
with ACTN4 mutations also show segmental weak lin-
ear, irregular granular, and punctuate appearance of 
ACTN4 staining surrounding the glomerular capillary 
wall [64]. These abnormalities could potentially be direct 
results of increased binding affinity to F-actin of mutant 
actn4, resulting in disruption of actin reorganization or 
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assembly. Additionally, Weins et  al. also reported that 
two other known interacting proteins cortactin and 
synaptopodin were also present in the mutant Actn4/F-
actin aggregates [60]. The sequestration of these bind-
ing partners, which play important roles in podocyte 
function, could alter the response of podocytes to envi-
ronmental stressors. Michaud et  al. used conditionally 
immortalized mouse podocytes infected with adenovi-
ral constructs containing WT or K256E murine Actn4 
to assess the functional consequence of mutations on 
subcellular localization, adhesion, spreading, migration, 
and formation of foot process-like peripheral projections 
[65]. They found that mutant K256E Actn4 was detected 
predominantly in the Triton-insoluble fraction of cel-
lular extraction, and localizes almost exclusively along 
actin stress fibers. On the other hand, WT Actn4 was 
detected primarily in the Triton-soluble fraction of cel-
lular extraction, localized to membrane-associated corti-
cal actin and focal adhesions, with some expression along 
stress fibers. Podocytes overexpressing WT or mutant 
K256E Actn4 show similar adhesion to the extracellular 
matrix (collagen-I). However, podocytes overexpressing 
mutant K256E Actn4 exhibit significantly reduced ability 
to spread and migrate on collagen-I, and have a reduced 
mean number of actin-rich peripheral projections (remi-
niscent of podocyte foot processes in cell culture) com-
pared to WT, perhaps all due to mutant Actn4/F-actin 
aggregates formation.
The sequestration of mutant ACTN4 together with 
F-actin in cellular aggregates can prevent ACTN4 to 
serve as transcriptional co-regulator. ACTN4 harbors 
a functional nuclear receptor interaction motif LXX 
LL (where L is leucine, X can be any amino acids) [41]. 
Khurana el al reported that a portion of WT ACTN4 
can move to the podocyte nucleus and stimulate nuclear 
RARα [42] and NF-ķB [46] mediated transcription. When 
the LXXLL motif is mutated to LXXAA, WT ACTN4 
(LXX AA) exhibits significant loss of the ability to poten-
tiate RARα mediated transcription. On the other hand, 
disease-causing mutant ACTN4, predominantly cyto-
plasmic, failed to translocate to the nucleus and show an 
inability to stimulate RARα-mediated transcription.
Mutations within ABD of ACTN4 could lead to greater 
degradation of the protein in the cell [56]. Yao et  al. 
reported that homozygous Actn4 KI mice showed mark-
edly decreased expression of Actn4 protein in homozy-
gous KI mice, and moderately decreased expression 
in heterozygous KI mice. Conditionally immortalized 
fibroblasts isolated from WT and homozygous K256E 
mice were used to compare actn4 protein synthesis and 
degradation rates in the cell. They found that the protein 
degradation rate of mutant Actn4 is much faster that WT 
Actn4. There is no difference in protein synthesis rates. 
The greater Actn4 degradation rate could potentially 
explain the lower level of Actn4 protein in homozygous 
KI mice compared to WT mice in kidney, lung, liver and 
brain. Rapid degradation of Actn4 in mutant fibroblasts 
can be reversed by the treating of a selective proteasome 
inhibitor lactacystin. This result suggests that mutant 
Actn4 may be degraded through the ubiquitin–protea-
some pathway. Interestingly, it was reported that ubiq-
uitin C-terminal hydrolase L1 (UCHL1) is up regulated 
in a subset of human glomerulopathies, including pri-
mary FSGS [66]. Reed et al. intercrossed K256E-Actn4pod 
with heterozygous UCHI1 KO mice [67]. They found 
that mice that are heterozygous for an Actn4 transgene 
but homozygous for UCHL1 KO (K256E-Actn4pod+/
UCHL1−/−) exhibited significantly ameliorated albumi-
nuria, glomerulosclerosis, and foot process enfacement 
at 10 weeks of age. This result suggested that preserving 
K255E/WT Actn4 heterodimers from proteolysis might 
help to maintain podocyte function.
Recently, Grgic et al. used translating ribosome affinity 
purification (TRAP) to isolate and compare podocyte-
specific mRNA expression between heterozygous Actn4 
KI mice and WT [68]. They found that among other up-
regulated genes in heterozygous Actn4 KI mice, myo-
tonic dystrophy protein kinase (Dmpk), a Rho-associated 
serine-threonine protein kinase, is also upregulated at the 
protein level in human FSGS kidney biopsies. The role of 
DMPK in the development of FSGS in humans has yet to 
be elucidated.
Conclusions
Mutations in the ACTN4 gene cause a highly penetrant, 
autosomal dominant form of familial FSGS in humans. 
Studies in Actn4 KO, Actn4 KI, and transgenic Actn4 
mouse models confirm the importance of this gene in 
kidney function. Even though several studies have shown 
that ACTN4 mutations lead to biochemical, biophysical, 
and cellular functional changes, more research is needed 
to elucidate the exact pathways by which these muta-
tions lead to podocyte injury, which may provide insights 
into therapeutic development. Since highly penetrant 
Mendelian forms of kidney disease caused by mutations 
in ACTN4 and other genes are rare examples where we 
can unequivocally identify the cause, the development 
of the specific therapies treating these diseases will be a 
proof of concept to advance individualized treatment in 
nephrology.
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